Materialise(US:MTLS)2025-10-28 13:30Financial Data and Key Metrics Changes - Consolidated revenue for Q3 2025 was €66.3 million, a decrease of 3.5% compared to the same period last year [15][16] - Gross profit margin remained strong at 56.8%, consistent with the margin for the first nine months of 2025 [15][23] - Adjusted EBIT for Q3 2025 was €2.9 million, with an adjusted EBIT margin of 4.4% [15][17] - Net profit for the quarter was €1.8 million, representing €0.03 per share [15][24] - Net cash position increased to €67.7 million, driven by strong free cash flow [15][25] Business Line Data and Key Metrics Changes - Materialise Medical achieved record revenue of €33.3 million, growing by over 10% compared to Q3 2024 [15][16] - Materialise Software revenue decreased by 7% to €10.3 million, impacted by macroeconomic headwinds [19][20] - Materialise Manufacturing revenue declined by 17% to €22.7 million, reflecting ongoing market challenges [22] Market Data and Key Metrics Changes - Materialise Medical accounted for 50% of total revenue, while Materialise Software and Manufacturing contributed 16% and 34%, respectively [16] - The software segment's recurring revenue increased to 83%, up from 74% in the same quarter last year [20] Company Strategy and Development Direction - The company continues to focus on growth in the medical segment, particularly in cardiac and trauma markets [5][8] - Investment in R&D for medical applications is expected to drive future growth [19] - The company is expanding its capabilities in the defense sector, leveraging additive manufacturing to address industry challenges [13][14] Management's Comments on Operating Environment and Future Outlook - Management maintains guidance for 2025 revenues in the range of €265 to €280 million and adjusted EBIT between €6 to €10 million [28] - The company remains confident in its resilience and ability to capture growth opportunities as market conditions improve [28] Other Important Information - The company has launched new versions of its software products, enhancing features and efficiency for users [8][10] - The defense sector is expected to see increased spending, particularly in Europe, which may benefit the company's offerings [13] Q&A Session Summary Question: Update on medical segment exposure and growth potential - Management indicated that existing markets like CMF and orthopedics are mature, while new markets such as cardiac and respiratory are expected to grow faster in the future [34] Question: Size of aerospace and defense as a percentage of revenue - Aerospace has shown continuous growth, while defense is a newer segment with potential for future growth [35] Question: Manufacturing profitability and recovery prospects - Management highlighted cost reduction measures and the need for recovery in European and automotive markets to improve profitability [38][39]